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A B S T R A C T
Ibuprofen is a widely used non-steroidal anti-inflammatory drug (NSAID) that exerts analgesic and anti-in-
flammatory actions. The transient receptor potential ankyrin 1 (TRPA1) channel, expressed primarily in noci-
ceptors, mediates the action of proalgesic and inflammatory agents. Ibuprofen metabolism yields the reactive
compound, ibuprofen-acyl glucuronide, which, like other TRPA1 ligands, covalently interacts with macro-
molecules. To explore whether ibuprofen-acyl glucuronide contributes to the ibuprofen analgesic and anti-in-
flammatory actions by targeting TRPA1, we used in vitro tools (TRPA1-expressing human and rodent cells) and in
vivo mouse models of inflammatory pain. Ibuprofen-acyl glucuronide, but not ibuprofen, inhibited calcium re-
sponses evoked by reactive TRPA1 agonists, including allyl isothiocyanate (AITC), in cells expressing the re-
combinant and native human channel and in cultured rat primary sensory neurons. Responses by the non-
reactive agonist, menthol, in a mutant human TRPA1 lacking key cysteine-lysine residues, were not affected. In
addition, molecular modeling studies evaluating the covalent interaction of ibuprofen-acyl glucuronide with
TRPA1 suggested the key cysteine residue C621 as a probable alkylation site for the ligand. Local administration
of ibuprofen-acyl glucuronide, but not ibuprofen, in the mouse hind paw attenuated nociception by AITC and
other TRPA1 agonists and the early nociceptive response (phase I) to formalin. Systemic ibuprofen-acyl glu-
curonide and ibuprofen, but not indomethacin, reduced phase I of the formalin response. Carrageenan-evoked
allodynia in mice was reduced by local ibuprofen-acyl glucuronide, but not by ibuprofen, whereas both drugs
attenuated PGE2 levels. Ibuprofen-acyl glucuronide, but not ibuprofen, inhibited the release of IL-8 evoked by
AITC from cultured bronchial epithelial cells. The reactive ibuprofen metabolite selectively antagonizes TRPA1,
suggesting that this novel action of ibuprofen-acyl glucuronide might contribute to the analgesic and anti-in-
flammatory activities of the parent drug.
1. Introduction
Ibuprofen, the first approved member of propionic acid derivatives,
is a classical non-steroidal anti-inflammatory drug (NSAID) widely used
for its analgesic and anti-inflammatory properties [1,2]. Ibuprofen is
indicated to relieve inflammation and several types of pain, including
headache, muscular pain, toothache, backache, and dysmenorrhea [2].
Therapeutic effects of ibuprofen are attributed to inhibition of prosta-
noid synthesis by a non-selective, reversible inhibition of both cy-
clooxygenase 1 (COX1) and 2 (COX2) [3,4].
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The transient receptor potential ankyrin 1 (TRPA1), coexpressed
with the TRP vanilloid 1 (TRPV1) in a subpopulation of primary sensory
neurons, is activated by exogenous compounds, such as allyl iso-
thiocyanate (AITC) and cinnamaldehyde [5], and by an unprecedented
series of reactive oxidative, nitrogen and carbonylative species (ROS,
RNS and RCS, respectively), including hydrogen peroxide (H2O2) and
the electrophilic α,β-unsaturated aldehydes, 4-hydroxynonenal and
acrolein [6–10]. Such compounds, via Michael addition or oxidation
reactions, covalently bind specific cysteine/lysine residues of the cy-
toplasmic amino-terminus [11,12], thus gating the channel. TRPA1 has
been proposed as a major pain transducer [13–15], because of its im-
plication in models of both inflammatory pain, including those evoked
by formalin [16] and carrageenan [17,18], and neuropathic pain, such
as those induced by nerve injury [19–21], or anticancer drugs [22,23].
Clinical interest for the therapeutic potential of TRPA1 blockade is
underlined by current clinical trials with TRPA1 antagonists [24]. Ex-
pression of TRPA1 is not limited to primary sensory neurons, as its
presence and functions have been documented in a variety of non-
neuronal cells, including some cells of the airway tissues, where its
activation evokes the release of proinflammatory cytokines, such as
interleukin-8 [25–27].
Ibuprofen is almost completely metabolized, via an oxidative reac-
tion to the inactive metabolites, carboxy-ibuprofen and 2-hydroxy-
ibuprofen, which are both eliminated in the urine [28,29]. However,
10–15% of ibuprofen is glucuronidated to ibuprofen-acyl glucuronide
[28]. Plasma levels of ibuprofen and ibuprofen-acyl glucuronide have
been assessed in patients receiving long-term administration of oral
doses of 600/800mg ibuprofen. The ibuprofen and ibuprofen-acyl
glucuronide ratio was ˜30 to 1, [30]. Although glucuronidation is
generally considered a detoxification pathway, acyl glucuronides un-
dergo molecular rearrangement to reactive metabolites, which may
covalently bind various macromolecules [30,31]. Therefore, we in-
vestigated whether ibuprofen-acyl glucuronide antagonizes TRPA1 and,
via this mechanism, contributes to the analgesic and anti-inflammatory
actions of ibuprofen. We found that ibuprofen-acyl glucuronide, but not
ibuprofen, attenuates excitatory and pro-inflammatory responses in
TRPA1-expressing cells in vitro and proalgesic responses in vivo elicited
by reactive agonists of the channel. Ibuprofen-acyl glucuronide also
selectively attenuated the TRPA1-dependent component of the proal-
gesic responses evoked in vivo by formalin or carrageenan, thus un-
derlying the hypothesis that TRPA1 targeting by ibuprofen-acyl glu-
curonide contributes to both analgesic and anti-inflammatory effects of
ibuprofen.
2. Materials and methods
2.1. Animals
In vivo experiments and tissue collection were carried out according
to European Union (EU) guidelines and Italian legislation (DLgs 26/
2014, EU Directive application 2010/63/EU) for animal care proce-
dures, and under the University of Florence research permit #194/
2015-PR. C57BL/6 J mice (male, 20–22 g, 6 weeks; Envigo, Milan,
Italy); TRPA1-deficient (Trpa1−/−) mice (25–30 g, 5–8 weeks) [32] or
Sprague-Dawley rats (male, 75–100 g, Envigo, Milan, Italy) were used.
Animals were housed in a temperature- and humidity-controlled vi-
varium (12-hour dark/light cycle, free access to food and water). An-
imal studies were reported in compliance with the ARRIVE guidelines
[33].
Group size of n=6 animals for behavioral experiments were de-
termined by sample size estimation using G*Power (v3.1) [34] to detect
size effect in a post-hoc test with type 1 and 2 error rates of 5 and 20%,
respectively. Allocation concealment was performed using a randomi-
zation procedure (http://www.randomizer.org/). Experiments were
done in a quiet, temperature-controlled (20–22 °C) room between 9
a.m. and 5 p.m. and were performed by an operator blinded to drug
treatment. Animals were euthanized with inhaled CO2 plus 10–50% O2.
For the in vitro experiments we used a total of 10 rats and 42 mice.
2.2. Reagents and cells
HC-030031 [2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-
purin-7-yl)-N-(4-isopropylphenyl) acetamide] was synthesized as pre-
viously described [35]. If not otherwise indicated, reagents were ob-
tained from Sigma-Aldrich (Milan, Italy). Human embryonic kidney
293 (hHEK293, American Type Culture Collection; ATCC® CRL-1573™)
cells, HEK293 cells stably transfected with cDNA for human TRPA1
(hTRPA1-HEK293), or with the cDNA for human TRPV1 (hTRPV1-
HEK293), or with the cDNA for human TRPV4 (hTRPV4-HEK293), or
with cDNA for both human TRPA1 and human TRPV1 (hTRPA1/V1-
HEK293) channels, were cultured as previously described [36–39].
hHEK293 cells were transiently transfected with the cDNAs (1 μg) co-
difying for wild type (Wt) (hTRPA1-HEK293) or mutant human TRPA1
(C619S, C639S, C663S, K708Q; 3C/K-Q hTRPA1-HEK293) [11] using
the jetPRIME transfection reagent (Poliyplus-transfection® SA, Thermo
Scientific, Monza, Milan), according to the manufacturer’s protocol.
Human embryonic lung fibroblasts (IMR90; ATCC® CCL-186™) were
used as a model of human cells constitutively expressing the TRPA1
channel and were cultured in Dulbecco′s Modified Eagle′s Medium
(DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM glu-
tamine, 100 U penicillin and 100 μg/ml streptomycin, according to the
manufacturer’s instructions. Normal human bronchial epithelial cells
(NHBE; Lonza Group Ltd, Basel, Switzerland) were cultured in NHBE
growth medium, according to the manufacturer’s instructions. All cells
were cultured in an atmosphere of 95% air and 5% CO2 at 37 °C. For all
cell lines, the cells were used when received without further authenti-
cation.
Rodent primary sensory neurons were isolated from dorsal root
ganglia (DRGs) taken from Sprague-Dawley rats and cultured as pre-
viously described [35]. Briefly, ganglia were bilaterally excised under a
dissection microscope and transferred in Hank's balanced salt solution
(HBSS) containing 2mg/ml collagenase type 1 A and 1mg/ml trypsin,
for enzymatic digestion (30min, 37 °C). Ganglia were then transferred
to warmed DMEM containing 10% FBS, 10% horse serum, 2mM L-
glutamine, 100 U/ml penicillin and 100mg/ml streptomycin and dis-
sociated in single cells by several passages through a series of syringe
needles (23–25 G). Medium and ganglia cells were filtered to remove
debris and centrifuged. The pellet was resuspended in DMEM with
added 100 ng/ml mouse-nerve growth factor and 2.5 mM cytosine-b-D-
arabino-furanoside free base. Neurons were then plated on 25 mm-
diameter glass coverslips coated with poly-L-lysine (8.3 μM) and la-
minin (5 μM). DRG neurons were cultured for 3–4 days before being
used for calcium imaging experiments.
2.3. Calcium imaging assay
Single cell intracellular calcium was measured in untransfected and
in hTRPA1-HEK293, hTRPV1-HEK293, hTRPV4-HEK293, hTRPA1/V1-
HEK293, 3C/K-Q hTRPA1-HEK293 cells, IMR90 fibroblasts, NHBE
cells, or in rat DRG neurons. Plated cells were loaded with 5 μM Fura-
2 AM-ester (Alexis Biochemicals; Lausen, Switzerland) added to the
buffer solution (37 °C) containing the following (in mM): 2 CaCl2; 5.4
KCl; 0.4 MgSO4; 135 NaCl; 10 D-glucose; 10 HEPES and 0.1% bovine
serum albumin at pH 7.4. After loading (40min), cells were washed and
transferred to a chamber on the stage of an Olympus IX81 microscope
for recording. Cells were excited alternatively at 340 and 380 nm and
recorded with a dynamic image analysis system (XCellence Imaging
software; Olympus srl, Milan, Italy). To evoke a TRPA1-dependent
calcium response, cells and neurons were challenged with AITC
(1–1000 μM), acrolein (10 μM), hydrogen peroxide (H2O2, 500 μM),
icilin (30 μM), zinc chloride (ZnCl2, 1 μM) or menthol (100 μM). Buffer
solution containing 1% dimethyl sulfoxide (DMSO) was used as vehicle.
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The selective TRPV1 agonist, capsaicin (0.1 μM), was used in hTRPV1-
HEK293, in hTRPA1/V1-HEK293 and, to identify TRPV1-expressing
neurons and KCl (50mM), to identify the entire neuronal population
[40]. The selective TRPV4 agonist, GSK1016790 A (0.1 μM), was used
in hTRPV4-HEK293 cells. hTRPA1-HEK293, hTRPV1-HEK293,
hTRPV4-HEK293, hTRPA1/V1-HEK293, IMR90 fibroblasts and NHBE
cells were challenged with the activating peptide (AP) of the human
proteinase activated receptor 2 (hPAR2) (hPAR2-AP, SLIGKV-NH2, 100
μM).
Cells or neurons were pre-exposed (10min) to ibuprofen-acyl glu-
curonide (1–300 μM), ibuprofen (100 μM), HC-030031 (0.1–30 μM),
capsazepine (10 μM), HC-067047 (10 μM) or vehicle (0.3% DMSO)
before the addition of the TRPA1, TRPV1 or TRPV4 agonists. Results
were expressed as the percentage of the increase in R340/380 over
baseline, normalized to the maximum effect induced by ionomycin (5
μM) added at the end of each experiment (% Change in R340/380); or as
the percentage of the inhibitory effect on the calcium response evoked
by AITC (% AITC response) for constructing the concentration-response
curves in the presence of ibuprofen-acyl glucuronide.
2.4. Behavioral experiments
2.4.1. Treatment protocols
C57BL/6 J mice were injected in the plantar surface of the hind paw
(intraplantar, i.pl., 20 μl/paw) with a mixture of AITC, acrolein or ZnCl2
(all, 10 nmol) [40] and ibuprofen-acyl glucuronide (0.3–300 nmol) or
HC-030031 (0.3–300 nmol) or ibuprofen (300 nmol), or capsaicin
(1 nmol) and capsazepine (300 nmol), or hypotonic solution (0.27%
NaCl) and HC-067047 (300 nmol), or their vehicle (4% DMSO and 4%
tween 80 in 0.9% NaCl), and acute nociceptive responses were recorded
over the next 10min [40,41]. Some C57BL/6 J mice were treated in-
traperitoneally (i.p.) with ibuprofen-acyl glucuronide (1, 10 and
100mg/kg), HC-030031 (1, 10 and 100mg/kg), ibuprofen (1, 10 and
100mg/kg) or their vehicle (4% DMSO and 4% tween 80 in 0.9% NaCl)
and 30min after treatment the acute nociceptive response to i.pl. in-
jection of AITC (10 nmol) was recorded over the next 10min [40].
Other C57BL/6 J mice were treated intraperitoneally (i.p.) with ibu-
profen-acyl glucuronide (10 and 100mg/kg), ibuprofen (10 and
100mg/kg), HC-030031 (100mg/kg) [40], capsazepine (4mg/kg)
[40], HC-067047 (10mg/kg) [42], or their vehicle (4% DMSO and 4%
tween 80 in 0.9% NaCl) and 30min after treatment the acute noci-
ceptive responses to i.pl. injection of acrolein and ZnCl2 (all, 10 nmol),
capsaicin (1 nmol) or hypotonic solution (0.27% NaCl) were recorded
over the next 10min [40].
For the carrageenan model, C57BL/6 J mice were injected (i.pl.,
20 μl/paw) with carrageenan (300 μg), or its vehicle (0.9% NaCl), and
mechanical allodynia was recorded 180min after injection [17]. Some
C57BL/6 J mice were treated (150min after carrageenan) by i.pl.
(20 μl/paw) injection with ibuprofen-acyl glucuronide, ibuprofen (all,
100 nmol), or a mixture of ibuprofen-acyl glucuronide or ibuprofen and
HC-030031 (all, 100 nmol), or their vehicle (all 4% DMSO and 4%
tween 80 in 0.9% NaCl). Additional C57BL/6 J mice were treated
(150min after carrageenan) with i.p. ibuprofen-acyl glucuronide, ibu-
profen (both 10 and 100mg/kg), HC-030031 (100mg/kg), in-
domethacin (30mg/kg) or their vehicles (4% DMSO and 4% tween 80
in 0.9% NaCl) [40]. Some Trpa1−/− mice were treated (150min after
carrageenan) with i.p. ibuprofen-acyl glucuronide (100mg/kg).
For the formalin test, C57BL/6J mice were injected (i.pl., 20 μl/
paw) with formalin (0.5% in 0.9% NaCl) and the acute nociceptive
response was monitored over the next 60min and reported as phase I
(0–10min) and phase II (11–60min) [16]. Some animals were pre-
treated by i.pl. (20 μl/paw) injection (10min before) with ibuprofen-
acyl glucuronide and ibuprofen (both 100 nmol) or their vehicle (all 4%
DMSO and 4% tween 80 in 0.9% NaCl) or with i.p. ibuprofen-acyl
glucuronide, ibuprofen (both 10 and 100mg/kg, 30 min before), HC-
030031 (100mg/kg, 60min before) [16] and indomethacin (30mg/kg,
30min before) [40].
2.4.2. Acute nociceptive test and Von Frey hair test
Immediately after the i.pl. (20 μl/paw) injection with tested com-
pounds, mice were placed inside a plexiglass chamber and the total
time spent in lifting/licking the injected hind paw, as an indicative time
of acute nociceptive response, was recorded for 10min. The i.pl. in-
jection with vehicles of tested compounds produced nociceptive beha-
vior for a maximum of 2 s. Mechanical allodynia was measured in mice
by the up-and-down paradigm [43]. Briefly, mice were placed in-
dividually in a plexiglass chamber designed for the evaluation of me-
chanical thresholds [43] and were habituated to the room temperature
for at least 1 h before the test. Then, a series of 7 Von Frey hairs in
logarithmic increments of force (0.07, 0.16, 0.4, 0.6, 1, 1.4, 2 g) was
used to stimulate the injected hind paw. The response was considered
positive when the mouse strongly withdrew the paw. The stimulation
started with the 0.6 g filament. The von Frey hairs were applied with
sufficient force to cause slight buckling and held for approximately
2–4 s. Absence of response after 5 s led to the use of a filament with
increased weight, whereas a positive response led to the use of a weaker
(i.e. lighter) filament. Six measurements were collected for each mouse
or until four consecutive positive or negative responses occurred. The
50% mechanical withdrawal threshold (expressed in g) response was
then calculated from these scores, as previously described [43,44].
Mechanical nociceptive threshold was determined before (basal level)
and after different treatments.
2.5. Prostaglandin E2 assay
C57BL/6 J or Trpa1−/− mice were injected (i.pl. 20 μl/paw) with
carrageenan (300 μg) or its vehicle (0.9% NaCl) and 180min after
treatment the injected paws were collected, weighed, frozen in liquid
nitrogen and homogenized in sodium phosphate buffer (PBS 0.1 M, pH
7.4) containing indomethacin (20 μM) to avoid further activation of
COX. Homogenates were centrifuged at 9000×g for 20min at 4 °C [45].
Supernatants were collected and PGE2 levels were measured by enzyme
immunoassay (Abcam, Cambridge, UK), according to the manu-
facturer’s instructions. Some C57BL/6 J were treated (150min after
carrageenan) by i.pl. (20 μl/paw) injection with ibuprofen-acyl glu-
curonide, ibuprofen (both, 100 nmol) or their vehicles (4% DMSO and
4% tween 80 in 0.9% NaCl). Other animals were treated (150min after
carrageenan) by i.p. injection with ibuprofen-acyl glucuronide, ibu-
profen (both, 100mg/kg), HC-030031 (100mg/kg, i.p.), indomethacin
(30mg/kg, i.p.), or their vehicles (4% DMSO and 4% tween 80 in 0.9%
NaCl).
2.6. Molecular modeling
2.6.1. Protein structure refinement
Molecular modeling studies were performed using the structure of
the human TRPA1 ion channel determined by electron cryo-microscopy
(PDB code 3J9P) [46]. The missing side chains of partially resolved
residues as well as the missing loop sequences within the protein core
structure were automatically reconstructed by using Modeller software
[47]. The refined structure was then energy minimized in explicit water
environment, after being embedded in a lipid bilayer. The creation of
the phospholipid bilayer constituted by POPC (1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine) molecules and the insertion of the protein
inside it were performed using Visual Molecular Dynamics (VMD)
software [48]. The energy minimization was then carried out with
AMBER software, version 16. The system was solvated with a 15 Å
water cap on both the “intracellular” and the “extracellular” sides using
the TIP3P solvent model, while chloride ions were added as counterions
to neutralize the system. The Lipid14 parameters [49] were assigned to
POPC molecules. Three sequential minimization stages, each consisting
of 8000 steps of steepest descent followed by conjugate gradient, were
F. De Logu, et al. Pharmacological Research 142 (2019) 127–139
129
thus performed. In the first stage, a position restraint of 100 kcal/
mol·Å2 was applied on the whole protein and phospholipid bilayer in
order to uniquely minimize the positions of the water molecules. In the
second stage, the same position restraint was only applied on the pro-
tein residues, thus leaving the phospholipid molecules free, while in the
last stage only the protein α carbons were restrained with a harmonic
potential of 30 kcal/mol·Å2.
2.6.2. Ibuprofen-acyl glucuronide -TRPA1 covalent binding analysis
Molecular docking studies were performed on the structurally re-
fined and energy minimized structure of hTRPA1 using the covalent
docking protocol implemented in Gold software [50]. The calculations
were performed selecting C621, C641 and C665 as the covalently
modified residues and the acyl portion of ibuprofen-acyl glucuronide
belonging to (S)-ibuprofen as the ligand moiety covalently bound to the
residues. For each of the three S-acyl-cysteine thioester adducts, 100
different ligand binding orientations were evaluated, and the top-scored
disposition was considered for further analyses. The three ligand-pro-
tein complexes obtained were then subjected to molecular dynamic
(MD) simulations with AMBER 16. Each complex was initially subjected
to three stages of energy minimization as performed for protein re-
finement. Subsequently, the temperature of the system was gradually
raised from 0 to 300 K through a brief constant-volume MD simulation
where a position restraint of 30 kcal/mol·Å2 was applied on the protein
Fig. 1. Ibuprofen-acyl glucuronide antagonizes the human recombinant TRPA1. (A) Chemical structure of ibuprofen (Ibu) and ibuprofen acyl-β-D-glucoronide (IAG). (B)
Typical traces of the effect of IAG (100 μM) or its vehicle (Veh IAG) on calcium responses evoked by AITC (5 μM) in hTRPA1-HEK293. (C) Concentration-response
curves of the inhibitory effect of IAG and HC-030031 (HC-03), on the calcium response evoked by AITC (5 μM) in hTRPA1-HEK293 cells. (D) Effect of IAG (100 μM),
HC-030031 (HC-03, 30 μM) and Ibu (100 μM) on the calcium responses evoked by acrolein (ACR, 10 μM), hydrogen peroxide (H2O2, 500 μM), icilin (30 μM), zinc
chloride (ZnCl2, 1 μM) and the activating peptide (AP) of the human proteinase activated receptor 2 (hPAR2) (hPAR2-AP, 100 μM). (E) Effect of IAG (100 μM) on the
3C/K-Q hTRPA1-HEK293 cells evoked by menthol (100 μM). (F) Effect of IAG (100 μM) and capsazepine (CPZ, 10 μM) on the calcium responses evoked by capsaicin
(CPS, 0.1 μM) in hTRPV1-HEK293 cells. (G) Effect of IAG (100 μM), CPZ (10 μM) and HC-03 (30 μM) on the calcium response evoked by CPS (0.1 μM) and AITC (10
μM) in hTRPA1/V1-HEK293 cells. (H) Effect of IAG (100 μM) and HC-067047 (HC-06, 10 μM) on the calcium response evoked by GSK1016790 A (GSK, 0.1 μM) in
hTRPV4-HEK293 cells. (I) Effect of IAG (100 μM), Ibu (100 μM) and indomethacin acyl-β-D-glucuronide (IndoAG, 100 μM) on the calcium response evoked by AITC
(5 μM) in hTRPA1-HEK293 cells. Values are mean ± s.e.m of n> 50 cells from at least 3 different experiments for each condition. Veh indicates vehicle of AITC,
ACR, H2O2, icilin, ZnCl2 and hPAR2-AP, dash (-) indicates vehicles of IAG, HC-03, ibu, CPZ, and HC-06. *P < 0.05 vs. Veh; §P < 0.05 vs. AITC, ACR, H2O2, icilin,
ZnCl2, CPS or GSK. One-way ANOVA and post-hoc Bonferroni’s test.
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α carbons. The system was then relaxed through a 500 ps constant-
pressure MD simulation in which the harmonic potential applied on the
protein α carbons was gradually removed and a Langevin thermostat
was used to keep the temperature at 300 K. Finally, 20 ns of constant-
pressure MD simulation production were performed by leaving the
whole system free and using the Monte Carlo barostat with anisotropic
pressure scaling for pressure control. All simulations were performed
using particle mesh Ewald electrostatics with a cutoff of 10 Å for non-
bonded interactions and periodic boundary conditions. A simulation
step of 2.0 fs was employed, as all bonds involving hydrogen atoms
were kept rigid using SHAKE algorithm. The Lipid14 parameters were
assigned to POPC molecules, while GAFF parameters were used for the
ligand, whose partial charges were calculated with the AM1-BCC
method as implemented in the Antechamber suite of AMBER 16. Linear
interaction energy (LIE) evaluations were performed between the li-
gand (i.e. the atoms constituting the S-acyl moiety belonging to ibu-
profen of the covalent adduct) and the protein residues located within a
12 Å radius from it. The ccptraj analysis program module of AMBER 16,
was employed for the calculations, using the trajectories extracted from
the last 10 ns of MD simulation, for a total of 100 snapshots (with a time
interval of 100 ps).
2.7. IL-8 release assay
For IL-8 ELISA assay, NHBE cells were seeded in complete culture
medium in 48-well plates, grown to ˜80-90% confluence, and incubated
overnight in serum-free medium before treatments. All the treatments
were then performed in serum free medium. Cells were pretreated
(30min) with HC-030031 (50 μM), ibuprofen-acyl glucuronide and
ibuprofen (both, 100 μM) or vehicle (1% DMSO) before incubation
(18 h at 37 °C in 5% CO2) with freshly prepared AITC (10–30 μM) and
TNF-α (0.2 nM). Supernatants were then collected, and the human IL-8
content was assayed using a paired antibody quantitative ELISA kit
(Invitrogen, Milan, Italy) (detection limit: 5 pg/ml). The assay was
performed according to the manufacturer’s instructions.
2.8. Data and statistical analysis
All data were expressed as mean ± s.e.m or confidence interval
(CI). Statistical analysis was performed by the one-way analysis of
variance (ANOVA) followed by the post-hoc Bonferroni’s test for com-
parisons of multiple groups. For behavioural experiments with repeated
measures, the two-way ANOVA followed by the post-hoc Bonferroni’s
test was used. Statistical analysis was performed on raw data using
GraphPad software (GraphPad Prism version 6.00, San Diego, CA,
USA). P < 0.05 was considered statistically significant.
3. Results
3.1. Ibuprofen-acyl glucuronide antagonizes human and rodent TRPA1
The ability of ibuprofen-acyl glucuronide to affect TRPA1-mediated
calcium responses was studied by using a single cell assay in human and
rodent cells expressing TRPA1. Ibuprofen-acyl glucuronide did not
evoke per se any calcium response in hTRPA1-HEK293 cells (Fig. 1B,I).
However, ibuprofen-acyl glucuronide, like the selective TRPA1 an-
tagonist, HC-030031, inhibited in a concentration-dependent manner
calcium response evoked by AITC [IC50, 30 (CI, 22–40) μM and 3 (CI,
1.4–6) μM, respectively] (Fig. 1C). Ibuprofen-acyl glucuronide reduced
calcium responses evoked by additional reactive TRPA1 agonists, such
as acrolein or hydrogen peroxide (H2O2) (Fig. 1D), but did not affect the
responses by non-reactive agonists, icilin and zinc chloride (ZnCl2)
(Fig. 1D), which do not act by binding key cysteine residues of TRPA1
[51,52]. HC-030031 abolished the calcium responses evoked by both
reactive and non-reactive agonists (Fig. 1D). Ibuprofen-acyl glucur-
onide did not attenuate the rapid calcium responses evoked by acute
exposure to the activating peptide (AP) of the human protease-activated
receptor 2 (hPAR2) (hPAR2-AP) (Fig. 1D). This finding supports the
selectivity of ibuprofen-acyl glucuronide. The ability of ibuprofen-acyl
glucuronide to inhibit TRPA1 by binding key cysteine and lysine re-
sidues was further proved by the study of the mutated human TRPA1
(3C/K-Q hTRPA1), which lacks the cysteine and lysine residues, re-
quired for channel activation by reactive agonists, and which responds
to menthol [9,11,12]. Calcium responses to menthol (100 μM) were
unaffected by ibuprofen-acyl glucuronide in 3C/K-Q hTRPA1-HEK293
cells (Fig. 1E).
Selectivity of ibuprofen-acyl glucuronide for TRPA1 was robustly
confirmed by a series of observations. In hTRPV1-HEK293, calcium
responses to the TRPV1 agonist, capsaicin, were ablated by the TRPV1
selective antagonist, capsazepine, but were unaffected by ibuprofen-
acyl glucuronide (Fig. 1F). In hTRPA1/TRPV1-HEK293 co-expressing
cells, responses to capsaicin were attenuated by capsazepine, but not by
ibuprofen-acyl glucuronide, whereas responses to AITC were ablated by
ibuprofen-acyl glucuronide and HC-03003, but not by capsazepine
(Fig. 1G). Moreover, in hTRPV4-HEK293 cells, calcium responses to the
selective TRPV4 agonist, GSK1016790 A, were ablated by a TRPV4
antagonist, HC-067047, but were unaffected by ibuprofen-acyl glucur-
onide (Fig. 1H). Ibuprofen did not evoke per se any calcium responses
and did not affect the calcium responses evoked by AITC, acrolein or
H2O2 in hTRPA1-HEK293 cells (Fig. 1D,I). The glucuronidated meta-
bolite of indomethacin, acyl-β-D-glucuronide, neither evoked calcium
response nor reduced the calcium response evoked by AITC in hTRPA1-
HEK293 cells (Fig. 1I).
Ibuprofen-acyl glucuronide also inhibited the AITC-evoked calcium
response in IMR90 cells, a cell line where TRPA1 was originally cloned
[53], (Fig. 2A), and which constitutively expresses the channel. Ibu-
profen-acyl glucuronide [IC50s, 60 (CI, 45–88) μM] and HC-030031
[IC50s, 3 (CI, 2–6) μM] reduced AITC-evoked calcium responses
(Fig. 2B,C). Ibuprofen-acyl glucuronide failed to attenuate rapid cal-
cium responses evoked by acute exposure to hPAR2-AP (Fig. 2C). Ibu-
profen-acyl glucuronide [IC50, 50 (CI, 40–70) μM] and HC-030031
[IC50, 1 (CI, 0.3–1.8) μM] reduced AITC-evoked calcium responses in
cultured rat dorsal root ganglion (rDRG) neurons, which express the
native TRPA1 (Fig. 2D–F). Ibuprofen-acyl glucuronide did not affect
calcium responses to other excitatory stimuli, such as capsaicin and
high potassium chloride (KCl) (Fig. 2G). Thus, ibuprofen-acyl glucur-
onide was able to selectively block the human and rodent TRPA1
channel.
3.2. Mode of TRPA1 targeting by ibuprofen-acyl glucuronide
A covalent docking approach was applied to evaluate the binding
mode of the possible covalent adducts formed by transacylation of
ibuprofen-acyl glucuronide with residues C621, C641 and C665, since
the mutation of these residues abolished the inhibitory activity of the
ligand on TRPA1. Moreover, these solvent accessible residues are lo-
cated in an allosteric nexus of the TRPA1 channel, suitable for the de-
tection of electrophile agonists [46], and have been demonstrated to
exert a fundamental role in TRPA1 activation by reactive agonists like
AITC [11]. The structure of the human TRPA1 ion channel recently
determined by electron cryo-microscopy (PDB code 3J9P) was em-
ployed for this analysis [46]. After refining the protein structure (see
Materials and Methods for details), the covalent docking protocol im-
plemented in Gold software was applied to evaluate the binding or-
ientations of the thioester adducts formed by reaction of ibuprofen-acyl
glucuronide with C621, C641 and C665, corresponding to the acylation
of cysteine thiol groups with the ligand acyl moiety belonging to ibu-
profen. For each S-acyl-cysteine adduct, the top-scored binding dis-
position of the ligand was taken into account and further analyzed
through MD simulation studies. After embedding the covalently mod-
ified protein in a lipid bilayer and solvating the system with explicit
water molecules, 20 ns of MD simulation were performed (see Materials
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and Methods for details). The results were then analyzed in terms of
ligand-protein interaction energy, in order to evaluate the reliability of
the predicted covalent adducts from an energetic point of view. For this
purpose, the linear interaction energy (LIE) approach was employed.
LIE evaluations allow the calculation of the non-bonded interactions
between the ligand and the surrounding protein residues from the
trajectories generated through MD simulations. Electrostatic and van
der Waals energetic contributions are calculated for each MD snapshot
Fig. 2. Ibuprofen-acyl glucuronide antagonizes
the human and rat native TRPA1. (A) Typical
traces of the effect of pre-exposure (10min) to
Veh (vehicle) IAG/IAG (100 μM) on the cal-
cium response evoked by AITC (1 μM) and the
hPAR2-AP (100 μM) in IMR90 cells. (B)
Concentration-response curves of the in-
hibitory effect of IAG and HC-030031 (HC-03),
on the calcium response evoked by AITC
(1 μM) in IMR90 cells. (C) Pooled data of the
effect of IAG and HC-03 on the calcium re-
sponse evoked by AITC (1 μM) in IMR90 cells.
(D) Typical traces of the inhibitory effect of
pre-exposure (10 min) to Veh IAG/IAG
(100 μM) on the calcium response evoked by
AITC (10 μM), capsaicin (CPS, 0.1 μM) and KCl
(50mM) in rDRG neurons. (E) Concentration-
response curves of the inhibitory effect of IAG
and HC-03 on the calcium response evoked by
AITC in rDRG neurons. (F) Pooled data of the
effect of IAG and HC-03 on the calcium re-
sponse evoked by AITC (10 μM) in rDRG neu-
rons. (G) Pooled data of the effect of IAG
(100 μM) on the responses evoked by capsaicin
(CPS, 0.1 μM) or high potassium chloride (KCl,
50mM) in rDRG neurons. Values are mean
± s.e.m of n>25 cells from at least 3 dif-
ferent experiments for each condition. Veh
indicates vehicle of AITC, dash (-) indicates
vehicles of IAG and HC-03. *P < 0.05 vs. Veh;
§P < 0.05 vs. AITC. One-way ANOVA and
post-hoc Bonferroni’s test.
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and the obtained values are then used to derive the average total li-
gand-protein interaction energy. In this case, LIE evaluations were
performed between the atoms constituting the acyl moiety belonging to
ibuprofen of the three predicted S-acyl-cysteine covalent adducts and
the protein residues located within a radius of 12 Å. The MD trajectories
extracted from the last 10 ns of MD simulation were used for the cal-
culations, for a total of 100 snapshots (with a time interval of 100 ps).
The average LIE values (aLIE) were obtained for the three different
covalent complexes as the sum of the average electrostatic (EELE) and
van der Waals (EVDW) energy contributions expressed as kcal/mol
(Fig. 3A).
The linear interaction energy evaluations highlighted the S-acyl-
C621 thioester as the most energetically favored covalent adduct, pre-
senting a linear interaction energy value (-31.9 kcal/mol) exceeding
those estimated for the S-acyl-C641 and S-acyl-C665 covalent com-
plexes by about 12 and 18 kcal/mol, respectively. Interestingly, the
homolog of C621 in mouse TRPA1 (C622) was found to be the cysteine
residue that most affected TRPA1 activation by reactive agonists, since
its mutation completely abolished the responsiveness of TRPA1 to AITC
[12]. The average binding disposition of ibuprofen within the S-acyl-
C621 thioester adduct obtained from the last 10 ns of molecular dy-
namics simulation was obtained (Fig. 3B). The acyl chain belonging to
ibuprofen perfectly fits a small hydrophobic pocket constituted by I611,
F612, P617, V678, I679 and Y680, delimited by K610 and D677 from
one side and T684 from the other. In particular, the aromatic moiety of
the ligand lies on the P617 side chain, forming lipophilic interactions
with this residue, as well as with I622 and I679, while the p-isobutyl
group is sandwiched between F612 and V678, showing strong hydro-
phobic contacts with this latter residue. Moreover, the ligand carbonyl
oxygen forms a hydrogen bond with the backbone nitrogen of Y680 that
is maintained for about 80% of the entire molecular dynamics simu-
lation, thus contributing to the anchoring of the ligand to the hydro-
phobic pocket. Interestingly, the S-acyl-C621 thioester was the only
covalent complex in which a stable hydrogen bond between the ligand
portion and the surrounding protein residues was observed (Fig. 3B).
3.3. Ibuprofen-acyl glucuronide selectively inhibits TRPA1-mediated
nocifensor responses
Next, we speculated that ibuprofen-acyl glucuronide produces in
vivo antinociceptive effects via TRPA1 antagonism. The intraplantar
(20 μl/paw) administration of ibuprofen-acyl glucuronide or HC-
030031 dose-dependently reduced [ID50 of 4 (CI, 2–9) nmol, and ID50, 8
(CI, 3–23) nmol, respectively] the acute nociceptive response evoked by
the injection of AITC (intraplantar). Maximum inhibition on the noci-
ceptive responses evoked by AITC (intraplantar) was 72%±2% for
ibuprofen-acyl glucuronide and, 89%±1.7% for HC-030031 (n=6,
p < 0.05) (Fig. 4A). Acute nociceptive responses induced by in-
traplantar capsaicin and hypotonic solution (TRPV1 and TRPV4
-mediated responses, respectively) were attenuated by injection of the
respective channel antagonists, capsazepine and HC-067047, but were
unaffected by ibuprofen-acyl glucuronide (all intraplantar) (Fig. 4B).
The nociceptive response evoked by acrolein (intraplantar) was in-
hibited by ibuprofen-acyl glucuronide and HC-030031 (both in-
traplantar) (Fig. 4C). In contrast, ibuprofen-acyl glucuronide (in-
traplantar) failed to affect nociceptive response evoked by the non-
covalent agonist, ZnCl2 (intraplantar), which, however, was attenuated
by HC-030031 (intraplantar) (Fig. 4C). Ibuprofen intraplantar admin-
istration failed to affect the acute nociceptive response evoked by either
AITC, acrolein or ZnCl2 (all intraplantar) (Fig. 4C,D).
The systemic (intraperitoneal) administration of HC-030031, ibu-
profen-acyl glucuronide and ibuprofen dose-dependently [ID50s 7 (CI,
4–14) mg/kg, 10 (CI, 4–20) mg/kg and ID50s 27 (CI, 8–90) mg/kg,
respectively] reduced the nociceptive responses to AITC (intraplantar)
(Fig. 4E). Maximum inhibition by ibuprofen (42%±3%) was lower
than those produced by ibuprofen-acyl glucuronide (76%±4%) and
HC-030031 (83 ± 4%) (all 100mg/kg, n= 6 each, P < 0.05 ibu-
profen vs. both ibuprofen-acyl glucuronide and HC-030031) (Fig. 4E).
Systemic (intraperitoneal) ibuprofen-acyl glucuronide did not affect the
nociceptive responses evoked by either capsaicin or a hypotonic solu-
tion, which, however, were attenuated by the TRPV1 and TRPV4 an-
tagonists, capsazepine and HC067047, respectively (Fig. 4F). Systemic
(intraperitoneal) ibuprofen-acyl glucuronide (both, 10 and 100mg/kg)
reduced the nociception evoked by acrolein but not that evoked by
ZnCl2 (Fig. 4G,H), whereas only 100mg/kg, but not 10mg/kg (both
intraperitoneal) ibuprofen reduced the nociceptive responses evoked by
acrolein (Fig. 4G). Ibuprofen-acyl glucuronide at both 10 and 100mg/
kg was more effective than the respective doses of ibuprofen
(Fig. 4E,G). Finally, systemic (intraperitoneal) HC-030031 inhibited the
nociceptive responses evoked by both acrolein and ZnCl2 (Fig. 3G,H).
3.4. Ibuprofen-acyl glucuronide reduces TRPA1-dependent hyperalgesia
and nociception in models of inflammatory pain
We tested the ability of ibuprofen-acyl glucuronide to reduce me-
chanical allodynia evoked by intraplantar carrageenan injection in the
mouse hind paw. Carrageenan induces a prolonged mechanical allo-
dynia that is in part mediated by TRPA1 [17,18]. Ibuprofen-acyl glu-
curonide (intraplantar, 2.5 h after carrageenan) almost completely at-
tenuated mechanical allodynia (Fig. 5A), whereas an identical dose of
ibuprofen produced a partial inhibition (Fig. 5B). A combination of HC-
030031 and ibuprofen (both intraplantar) increased the effect of ibu-
profen alone, but did not further affect the inhibitory response to ibu-
profen-acyl glucuronide alone (Fig. 5A,B).
A low systemic (intraperitoneal) dose (10mg/kg) of ibuprofen-acyl
glucuronide, but not ibuprofen, significantly reduced carrageenan-
Fig. 3. Ibuprofen-acyl glucuronide interact with hTRPA1 in molecular dynamic
model, (A) Linear Interaction Energy (LIE) results for the three covalent com-
plexes of hTRPA1 obtained by transacylation of C621, C641 and C665 by IAG.
Data are expressed as kcal/mol. (B) Minimized average structure of the S-acyl-
C621 hTRPA1 ion channel. The covalent ligand is shown in orange, while the
protein residues are colored dark cyan.
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evoked mechanical allodynia (Fig. 5C). A systemic (intraperitoneal)
high dose (100mg/kg) of ibuprofen-acyl glucuronide or ibuprofen at-
tenuated the mechanical allodynia induced by carrageenan, but the
effect of ibuprofen-acyl glucuronide resulted higher than that of
ibuprofen (Fig. 5D, E). The combination of systemic (both in-
traperitoneal) HC-030031 and ibuprofen increased the inhibitory action
of ibuprofen alone, but did not affect the inhibitory response to ibu-
profen-acyl glucuronide alone (Fig. 5D, E). Systemic (intraperitoneal)
Fig. 4. Ibuprofen-acyl glucuronide inhibits noci-
ceptive responses evoked by reactive TRPA1
agonists in mice. (A) Dose-dependent in-
hibitory effect of intraplantar (i.pl., 20 μl/
paw) administration of IAG (0.3–300 nmol)
and HC-030031 (HC-03, 0.3–300 nmol) on
the acute nociceptive response evoked by i.pl.
allyl isothiocyanate (AITC, 20 nmol) in
C57BL/6 J mice. (B) Effect of IAG (300 nmol),
capsazepine (CPZ, 300 nmol) and HC-067047
(HC-06, 300 nmol) on the acute nociceptive
response evoked by i.pl. CPS (1 nmol) and
NaCl 0.27% in C57BL/6 J mice. (C) Effect of
i.pl. IAG (300 nmol), HC-03 (300 nmol) and
ibuprofen (Ibu, 300 nmol) on the nociceptive
response evoked by i.pl. acrolein (ACR,
10 nmol) and zinc chloride (ZnCl2, 10 nmol)
in C57BL/6 J mice. (D) Effect of Ibu
(300 nmol) on the nociceptive response
evoked by i.pl. AITC (20 nmol) in C57BL/6 J
mice. (E) Dose-response inhibitory effect of
intraperitoneal (i.p.) administration of IAG,
Ibu and HC-03 (all, 1–100mg/kg) on the
acute nociceptive response evoked by i.pl.
AITC (20 nmol) in C57BL/6 J mice. (F) Effect
of i.p. IAG (100mg/kg) CPZ (4mg/kg) and
HC-06 (10mg/kg) on the acute nociceptive
response evoked by i.pl. CPS (1 nmol) and
NaCl 0.27% in C57BL/6 J mice. (G) Effect of
i.p. IAG, Ibu (both, 10 and 100mg/kg) and
HC-03 (100mg/kg) on the acute nociceptive
response evoked by i.pl. ACR (10 nmol). (H)
Effect of IAG (100mg/kg) and HC-03
(100mg/kg) on the acute nociceptive re-
sponse evoked by i.pl. ZnCl2 (10 nmol).
Values are mean ± s.e.m of n= 6 mice for
each experimental condition. Veh indicates
vehicle of CPS, NaCl 0.27%, ACR, ZnCl2 and
AITC, dash (-) indicates vehicles of IAG, HC-
03, ibu, CPZ and HC-06. *P<0.05 vs. Veh;
§P < 0.05 vs. CPS or NaCl 0.27%, ACR and
ZnCl2, #P < 0.05 vs. HC-03 and IAG. One-
way ANOVA and post-hoc Bonferroni’s test.
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indomethacin partially inhibited carrageenan-induced mechanical al-
lodynia, and its combination with HC-030031 completely reversed
mechanical allodynia (Fig. 5F). Prostaglandin E2 (PGE2) assay from paw
homogenates of mice receiving carrageenan and treated by local (in-
traplantar, both 100 nmol) or systemic (intraperitoneal, both 100mg/
kg) ibuprofen-acyl glucuronide or ibuprofen revealed that both drugs
produced a similar and complete reduction in the tissue content of PGE2
(Fig. 5G,H). Systemic (intraperitoneal) indomethacin, but not HC-
030031, reduced PGE2 content in paw homogenates (Fig. 5H). Finally,
ibuprofen-acyl glucuronide attenuated carrageenan-evoked PGE2
release in TRPA1 deleted (Trpa1−/−) mice (Fig. 5I). Thus, ibuprofen-
acyl glucuronide maintains the ability of the parent compound to in-
hibit COXs.
Formalin injection (intraplantar) into the hind paw of the mouse
classically induces a biphasic nociceptive response, with phase I being
entirely dependent on TRPA1 [16], whereas phase II involves different
mechanisms, including the release of prostanoids. However, during
phase II, ongoing diffusion and spread of formalin along TRPA1-ex-
pressing nerves may elicit release of a large variety of different med-
iators, among which prostanoids [54], which may sensitize TRPA1
Fig. 5. Ibuprofen-acyl glucuronide produces anti-hyperalgesic effect in the carrageenan model of inflammatory pain. (A,B) Time course of the inhibitory effect of in-
traplantar (i.pl., 20 μl/paw) administration of IAG, Ibuprofen (Ibu) (both, 100 nmol) or of a mixture of IAG and HC-030031 (HC-03) or Ibu and HC-03 (all, 100 nmol)
on the mechanical allodynia evoked by i.pl. carrageenan (Cg, 300 μg) in C57BL/6 J mice. (C–E) Time course of the inhibitory effect of intraperitoneal (i.p.) ad-
ministration of IAG, Ibu (both, 10 and 100mg/kg) or a combination of IAG (100mg/kg) or ibu (100mg/kg) and HC-03 (100mg/kg) on the mechanical allodynia
evoked by i.pl. injection of Cg (300 μg) in C57BL/6 J mice. (F) Time course of the inhibitory effect of i.p. HC-03 (100mg/kg) and indomethacin (indo, 30mg/kg) or a
combination of both HC-03 (100mg/kg) and indo (30mg/kg) on the mechanical allodynia evoked by i.pl. injection of Cg (300 μg) in C57BL/6 J mice. (G) PGE2 levels
in paw homogenates measured 180min after i.pl. Cg (300 μg) in C57BL/6 J mice treated with IAG or Ibu (both, 100 nmol, i.pl.). (H) PGE2 levels in paw homogenates
measured 180min after i.pl. Cg (300 μg) in C57BL/6 J mice treated with IAG, Ibu, HC-03 (all, 100mg/kg, i.p.) or indo (30mg/kg, i.p.). (I) PGE2 levels in paw
homogenates measured 180min after i.pl. Cg (300 μg) in Trpa1−/− mice after IAG (100mg/kg, i.p.). Values are mean ± s.e.m of n= 6 mice for each experimental
condition. Veh indicates vehicle of Cg, dash (-) indicates vehicles of IAG, Ibu, HC-03 and indo. *P<0.05 vs. Veh; §P < 0.05 vs. Cg. #P < 0.05 vs. Cg/Ibu or Cg/HC-
03 or Cg/indo. One- and two-way ANOVA and post-hoc Bonferroni’s test.
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[55]. Ibuprofen-acyl glucuronide injection (intraplantar) attenuated
both phase I and phase II of the response (Fig. 6A). In contrast, ibu-
profen failed to affect phase I, but reduced phase II of the formalin test
(Fig. 6A). Systemic (intraperitoneal) administration of ibuprofen-acyl
glucuronide (10 and 100mg/kg) reduced phase I of the formalin test
(Fig. 6B). However, only 100mg/kg, but not 10mg/kg (i.p.), of ibu-
profen inhibited phase I of the formalin test (Fig. 6B). HC-030031 [16],
but not indomethacin [56], inhibited phase I of the formalin test
(Fig. 6B), whereas phase II was attenuated by both drugs (Fig. 6B).
3.5. Ibuprofen-acyl glucuronide reduces interleukin-8 release evoked by
TRPA1 stimulation from bronchial epithelial cells
TRPA1 expressed by various non-neuronal cells of the airways eli-
cits calcium responses and the release of proinflammatory cytokines,
including interleukin-8 (IL-8) [25–27]. The calcium responses evoked
by AITC in NHBE cells, which constitutively express TRPA1 [27], were
attenuated in a concentration-dependent manner by ibuprofen-acyl
glucuronide [IC50, 20 (CI, 13–40) μM] and HC-030031 [IC50,10 (CI,
8–12) μM] (Fig. 7A–C). Ibuprofen-acyl glucuronide failed to attenuate
the rapid calcium responses evoked by acute exposure to hPAR2-AP
(Fig. 7C). Exposure to AITC induced a concentration-related release of
IL-8 from cultured NHBE cells. This effect was attenuated in the pre-
sence of both ibuprofen-acyl glucuronide and HC-030031, but not in
the presence of ibuprofen (Fig. 7D). The observation that HC-030031,
ibuprofen-acyl glucuronide or ibuprofen did not affect IL-8 release
evoked by TNF-α indicated selectivity of ibuprofen-acyl glucuronide
and HC-030031 for the AITC-evoked effects (Fig. 7D).
4. Discussion
The COX inhibitor ibuprofen is widely used as a first line treatment
for the relief of pain and inflammation [2]. Glucuronide metabolites,
including those generated from ibuprofen, are generally considered
inactive and rapidly excreted compounds [57]. However, acyl glucur-
onides, undergoing hydrolysis, acyl migration and molecular re-
arrangement, exhibit chemical reactivity that allow them to covalently
bind various macromolecules [57–59]. TRPA1 belongs to such macro-
molecules that, through Michael addition, undergo nucleophilic attack
via specific cysteine/lysine residues [11,12]. Therefore, we hypothe-
sized that, as with various reactive compounds, ibuprofen-acyl glucur-
onide may react with TRPA1 [11,12]. Our major finding is that ibu-
profen-acyl glucuronide, but not its parent compound, ibuprofen,
antagonizes the proalgesic TRPA1 channel. This conclusion derives,
primarily, from the in vitro pharmacological profile of ibuprofen-acyl
glucuronide, which, unlike ibuprofen, selectively inhibits the
recombinant and native human TRPA1 and the native rodent channel in
nociceptors. Failure of the acyl derivative of indomethacin to affect
channel activity underlines the unique ability of ibuprofen-acyl glu-
curonide to target TRPA1.
Indication that the reactive property of ibuprofen-acyl glucuronide
is needed for efficient TRPA1 targeting is based on functional experi-
ments with the mutated form of the human TRPA1 channel, and on
docking and molecular dynamic simulations. The mutant hTRPA1-3C/
K-Q has the unique property of responding to non-reactive agonists,
such as menthol and icilin [9,11,12], but not to reactive agonists, in-
cluding AITC. In hTRPA1-3C/K-Q expressing cells, ibuprofen-acyl glu-
curonide did not affect the calcium response evoked by menthol. Thus,
the ability of ibuprofen-acyl glucuronide to inhibit TRPA1 depends on
the cysteine/lysine residues required for channel activation by elec-
trophilic/reactive agonists. Acyl-glucuronides are known to react by
transacylation with nucleophilic residues, leading to the formation of a
covalent adduct in which the acyl group, linked to the glucuronide, is
transferred to the nucleophilic atom of the residue [57–59]. To explore
the interaction between ibuprofen-acyl glucuronide G and the human
TRPA1 channel we performed computational studies, including mole-
cular docking and dynamic simulations, which predicted the formation
of covalent adducts between ibuprofen-acyl glucuronide and TRPA1.
Computational results with the mutated channel confirm that the in-
hibitory activity of ibuprofen-acyl glucuronide should be ascribed to its
interaction with one of the mutated residues. In vivo results that ibu-
profen-acyl glucuronide attenuated nociception evoked by reactive
TRPA1 agonists, but not those produced by non-reactive agonists, such
as icilin and zinc chloride, further supported the in vitro data and si-
mulation experiments, underlining that chemical reactivity is required
for TRPA1 targeting by ibuprofen-acyl glucuronide.
Additional in vivo data strengthen the conclusion obtained from in
vitro findings. Local injection of ibuprofen-acyl glucuronide in the
mouse hind paw prevented acute nociception elicited by local admin-
istration of the reactive TRPA1 agonists, AITC and acrolein, but was
ineffective against TRPV1 or TRPV4 agonists, indicating selectivity.
Notably, local injection of ibuprofen in the mouse hind paw did not
affect AITC or acrolein-evoked nociception. It is possible that following
i.pl. ibuprofen no ibuprofen-acyl glucuronide is generated locally, and
the action of TRPA1 agonists remains unopposed. However, about
10–15% of systemic ibuprofen is converted into ibuprofen-acyl glu-
curonide [28]. Thus, liver metabolism of a high dose of ibuprofen may
produce ibuprofen-acyl glucuronide levels such as to guarantee a local
concentration sufficient for inhibiting TRPA1. This hypothesis is sup-
ported by the observation that a high dose of systemic ibuprofen pro-
duced a partial attenuation of the nociception evoked by AITC.
Other NSAIDs, which derive from propionic acid, are known to
Fig. 6. Ibuprofen-acyl glucuronide produces antinociception effect in the formalin model of inflammatory pain. (A) Effect of intraplantar (i.pl., 20 μl/paw) administration of
IAG and ibuprofen (Ibu) (both, 100 nmol) on phase I and phase II of the formalin test. (B) Effect of intraperitoneal (i.p.) administration of IAG, Ibu (both, 10 and
100mg/kg), HC-030031 (HC-03, 100mg/kg) and indomethacin (Indo, 30mg/kg) on phase I and phase II of the formalin test. Values are mean ± s.e.m of n=6
mice for each experimental condition. Veh indicates vehicle of formalin, dash (-) indicates vehicles of IAG, Ibu, HC-03 and Indo. *P<0.05 vs. Veh; §P < 0.05 vs.
formalin. One-way ANOVA and post-hoc Bonferroni’s test.
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generate acyl glucuronides through hepatic metabolism. These acyl
derivatives could potentially possess anti-TRPA1 properties similar to
those of ibuprofen-acyl glucuronide. However, acyl glucuronidation
does not warrant per se that the metabolites possess the chemical re-
quirements for effective TRPA1 antagonism. For example, we failed to
detect any effect of the acyl derivative of indomethacin, acyl-β-D-glu-
curonide, in antagonizing AITC evoked calcium response in vitro, and
systemic indomethacin pretreatment did not affect the acute nocicep-
tion of phase I of the formalin test.
The analgesic action of ibuprofen derives from its ability to inhibit
COXs, and the ensuing blockade of prostaglandin generation [3,4]. This
feature also justifies the anti-inflammatory activity of ibuprofen. While
we provided evidence that ibuprofen-acyl glucuronide targets TRPA1,
we wondered whether it maintains the ability of the parent drug to
inhibit COXs. We also wondered whether ibuprofen-acyl glucuronide
ability to inhibit TRPA1 may exert anti-inflammatory activity in an
ibuprofen-independent manner. Carrageenan injection in rodent paw
evokes inflammation and prolonged allodynia that are in part mediated
by prostaglandins and in part by TRPA1 [17,18,40,60]. When allodynia
was analyzed, local (intraplantar) ibuprofen-acyl glucuronide elicited a
more robust inhibitory effect than that of an identical dose of ibuprofen,
and the combination with HC-030031 potentiated inhibition by ibu-
profen, but not that by ibuprofen-acyl glucuronide. Because both ibu-
profen-acyl glucuronide and ibuprofen ablated PGE2 levels it is possible
that the effect of locally administered ibuprofen-acyl glucuronide is due
to both COX inhibition and TRPA1 antagonism, whereas locally ad-
ministered ibuprofen solely inhibits COXs.
The study of systemic administered drugs strengthens this hypoth-
esis. A low dose of ibuprofen-acyl glucuronide, but not ibuprofen, at-
tenuated carrageenan-evoked allodynia. A high dose of ibuprofen-acyl
glucuronide or ibuprofen completely reversed or partially inhibited
allodynia, respectively. Furthermore, the combination of the high dose
of ibuprofen and HC-030031 potentiated the effect of ibuprofen alone.
Similar results were obtained with indomethacin (its metabolite, acyl-β-
D-glucuronide-indomethacin, does not target TRPA1) alone or in com-
bination with HC-030031. Thus, TRPA1 stimulation by endogenous
agonists generated by carrageenan-evoked inflammation cannot be
completely surmounted by the amount of ibuprofen-acyl glucuronide
generated by systemic metabolism of 100mg/kg ibuprofen. The ob-
servation that both systemic ibuprofen and ibuprofen-acyl glucuronide
completely inhibited PGE2 generation evoked by carrageen, indicates
that the metabolite maintains the COX inhibitory activity of the parent
drug, and justify the complete attenuation of carrageenan-evoked al-
lodynia by ibuprofen-acyl glucuronide which may simultaneously in-
hibit COXs and TRPA1. TRPA1 has been reported to contribute to in-
flammation by different pathways, including the release of pro-
inflammatory cytokines, such as IL-8 [25,26]. The present in vitro ob-
servation that ibuprofen-acyl glucuronide, but not ibuprofen, attenu-
ates the TRPA1-dependent ability of NHBE cells to release IL-8 under-
lines the contribution of the COX-independent anti-inflammatory
activity of the metabolite.
Our findings add new insights into the antinociceptive/anti-hyper-
algesic and anti-inflammatory activity of ibuprofen which, in addition
to COX inhibition, attenuates TRPA1 activity via ibuprofen-acyl glu-
curonide generation. This novel mechanism of ibuprofen/ibuprofen-
acyl glucuronide indirectly underlines the TRPA1 contribution to acute
nociception and delayed allodynia in various models of inflammatory
pain. Further studies are needed to establish whether TRPA1 antag-
onism by ibuprofen-acyl glucuronide contributes to the therapeutic
effect of ibuprofen in pain and inflammation in humans, and whether
ibuprofen-acyl glucuronide may have an efficacy and safety profile
different from its parent drug.
Fig. 7. Ibuprofen-acyl glucuronide antagonizes human native TRPA1 in NHBE cells reducing the IL-8 release. (A) Typical traces of the effect of pre-exposure (10min) to Veh
(vehicle) IAG/IAG (100 μM) on the calcium response evoked by AITC (1mM) and the hPAR2-AP (100 μM) in NHBE cells. (B,C) Concentration-response curves and
pooled data of the inhibitory effect of IAG (0.1–1000 μM) and HC-030031 (HC-03, 0.1–1000 μM) on the calcium response evoked by AITC (1mM) in NHBE cells. (D)
IL-8 release from NHBE cells exposed to AITC (10 and 30 μM) or TNF-α (0.2 nM) and pretreated with IAG and ibuprofen (Ibu) (both, 100 μM) and HC-03 (30 μM).
Values are mean ± s.e.m. of n> 25 cells from at least 3 different experiments for each condition or at least 3 independent experiments. Veh indicates vehicle of
AITC and TNF-α, dash (-) indicates vehicles of IAG, Ibu and HC-03. *P<0.05 vs. Veh; §P < 0.05 vs. AITC. One-way ANOVA and post-hoc Bonferroni’s test.
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